Clinical Trials Logo

Filter by:
NCT ID: NCT00652379 Completed - Insulin Resistance Clinical Trials

Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

Start date: June 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy. Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.

NCT ID: NCT00652366 Completed - Pancreatic Cancer Clinical Trials

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Start date: May 2008
Phase: Phase 2
Study type: Interventional

This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer. During a 4 week run-in period, all patients will receive Tarceva 100mg/day po plus gemcitabine 1000mg/m2 iv on days 1, 8,15 and 22. After 4 weeks, patients who have not developed rash, or only develop grade 1 rash, will be randomized to one of 2 groups. Group 1 will receive a starting dose of Tarceva 150mg po daily, increased in steps of 50mg every 2 weeks up to a maximum of 250mg/day po, until development of grade 2 rash or other dose-limiting toxicity. Group 2 will continue to receive Tarceva 100mg/day po. All patients will continue to receive gemcitabine 1000mg/m2 iv on days 1, 8 and 15 of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

NCT ID: NCT00649142 Completed - Clinical trials for Chronic Postherniotomy Pain

Predisposing Factors for Chronic Postherniotomy Pain

Start date: January 2007
Phase: N/A
Study type: Interventional

Chronic pain affects pain in 5-8% of patients more than a year after groin hernia repair. However no prospective study has investigated potential predisposing factors for development of pain, including genetic, psychosocial and detailed neurophysiological assessment of surgical method. The current study will assess the above factors in a prospective study.

NCT ID: NCT00647569 Completed - Incisional Hernia Clinical Trials

Trial of Collagen Mesh for Prevention of Ventral Hernia After Surgery for Advanced Pelvic Cancer

VRAM
Start date: April 2008
Phase: Phase 3
Study type: Interventional

The aim of the present project is to investigate whether use of biological mesh at the donor site of the rotation flap in closure of the abdominal wall reduce the frequency of incisional hernia formation compared to the usual abdominal wall closure after abdominal rotation flap operation in surgery for advanced pelvic cancer.

NCT ID: NCT00647504 Completed - Stent Thrombosis Clinical Trials

Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis

NIVUS
Start date: October 2007
Phase: N/A
Study type: Observational

Prospective clinical observational registry study including consecutive patients with clinical signs or symptoms due to in-stent restenosis (ISR) or definite (ARC criteria) stent thrombosis (ST). Study hypothesis: Initial Stent implantation quality (due to technique/problems) are possible major determinants of ST and ISR in real life practice. Both early, late, and very late ST, and ISR are important factors for long term outcome after initial stent implantation. Primary objective: - To elucidate the possible cause(s) of thrombosis or restenosis after stent implantation in real life practice by clinical, angiographic and IVUS evaluation. Secondary objective: - To describe the clinical manifestation [stable angina pectoris (AP), unstable AP, non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation MI] of the index event (inclusion). - To describe the characteristics of patient, lesion and procedure of the initial percutaneous coronary intervention (PCI). - To describe the antithrombotic pharmacological therapy preceding the index event. - To describe clinical outcome (death, MI, revascularization, CCS angina class) following treatment of the index event during 12 month follow-up. - To describe safety of the IVUS procedure (product or procedural related complications/ malfunctions).

NCT ID: NCT00647452 Completed - Healthy Clinical Trials

Very Low Density Lipoprotein (VLDL) Triglyceride Metabolism in Exercise

Start date: April 2008
Phase: N/A
Study type: Interventional

Purpose: To investigate VLDL-TG metabolism in exercise in healthy volunteers to determine the contribution of VLDL-TG in exercise and eventual gender differences

NCT ID: NCT00647244 Completed - HIV Infections Clinical Trials

Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients

SWAP
Start date: June 2008
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of switching from Retrovir to Tenofovir or Abacavir in HIV-infected patients

NCT ID: NCT00647179 Completed - Insulin Resistance Clinical Trials

Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment

Start date: February 2008
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the effects of chronic elevated growth hormone on metabolism and insulin sensitivity by studying acromegalic patients before and after treatment.

NCT ID: NCT00647127 Completed - Pain Clinical Trials

Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain

Start date: February 2008
Phase: Phase 3
Study type: Interventional

To compare the analgesic and anti-hyperalgesic effect of Buprenorphine and Fentanyl against experimental pain in skin, muscle and bone. The study will be performed with healthy volunteers.

NCT ID: NCT00646854 Completed - Clinical trials for Lymphoma, T-Cell, Peripheral

Alemtuzumab and CHOP in T-cell Lymphoma

ACT-1
Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine efficacy and safety of the monoclonal antibody MabCampath® (alemtuzumab) combined with chemotherapy in the treatment of T-cell lymphoma.